Miguel Zugman, Medical Oncologist at Einstein Hospital Israelita, shared on X:
“First-in-class RIPTAC in mAPMR.
Thrilled to see this beautifully presented by Benjamin Garmezy at ESMO26.
JNJ-6143 is a first-in-class RIPTAC targeting AR × BRD4, designed to induce BRD4 loss of function and prostate cancer cell death.”
At 50 mg QD in heavily pretreated mCRPC:
• 69% ORR (11/16)
• 13% CR + 56% PR
• 88% DCR
• Median DOR: 11.0 months
• 77% confirmed PSA50
• 48% confirmed PSA90
PSA responses were observed across high-risk molecular features, including AR amplification, AR-V7, AR LBD mutations, TP53, PTEN and RB1 alterations.
Safety was favorable, with mostly grade 1-2 TRAEs.
At 50 mg QD, the most frequent TRAEs were nausea, headache, increased cholesterol and hypertriglyceridemia.”
You can also read: DASL-HiCaP at ESMO 2026: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer
